GlassScriptPhysician profile
Robert Montgomery
NPI 1023421062
$9,259.87
in general payments reported to CMS, 2019-2025
14 companies · $7,233 in 2025
The $7,233 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $71.15 · 2023: $1,326 · 2024: $630 · 2025: $7,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,435 · Food and Beverage: $1,766 · Travel and Lodging: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,435.00 |
| Food and Beverage | $1,766.29 |
| Travel and Lodging | $987.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $6,779.61 | 2025 | |
| Abbott Laboratories | $1,744.29 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $308.35 | 2023-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $102.09 | 2024-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $93.46 | 2022-2025 | Wainua |
| Alnylam Pharmaceuticals INC. | $58.63 | 2025 | Onpattro |
| Lantheus Medical Imaging, INC. | $50.06 | 2023 | Definity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.33 | 2022-2023 | Jardiance |
| Bridgebio Pharma, INC. | $22.44 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $20.06 | 2024 | Xarelto |
| Lilly USA, LLC | $19.85 | 2025 | Mounjaro, Zepbound |
| Lexicon Pharmaceuticals, INC. | $18.06 | 2024 | |
| Pfizer INC. | $11.64 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.